GlassScriptPhysician profile
Olusola Olawale
NPI 1205327764
$1,162.21
in general payments reported to CMS, 2019-2025
9 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $260 · 2022: $428 · 2023: $154 · 2024: $88.20 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $416.99 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $212.16 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $164.82 | 2021-2024 | Austedo, Uzedy |
| Janssen Pharmaceuticals, INC | $92.77 | 2021-2023 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.36 | 2021-2025 | Caplyta |
| Abbvie INC. | $76.98 | 2022-2023 | |
| Lundbeck LLC | $70.80 | 2021-2025 | Abilify Asimtufii |
| Alkermes, INC. | $18.86 | 2023 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $17.47 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olusola Olawale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.